Final molecule (4), a PD-L-1 antagonist, dissociated the PD-1/PD-L-1 complex, restored cancer-reactive T-cells activation and incited adaptive immunity similar to anti-PD-L-1 antibodies. The gene discussed is CD274; the disease is cancer.